Related references
Note: Only part of the references are listed.Fingerprick blood samples to measure serum natalizumab concentrations
Alyssa A. Toorop et al.
MULTIPLE SCLEROSIS JOURNAL (2023)
Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease
Xavier Roblin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
Viktoria Bergqvist et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease
Desmond Chee et al.
JOURNAL OF CROHNS & COLITIS (2022)
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients
Marieke Zijlstra et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2021)
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)
Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review
Paul M. Overton et al.
PATIENT PREFERENCE AND ADHERENCE (2021)
Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples
Sophie E. Berends et al.
THERAPEUTIC DRUG MONITORING (2020)
Serum Biomarkers for Inflammatory Bowel Disease
Peng Chen et al.
FRONTIERS IN MEDICINE (2020)
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies
Konstantinos H. Katsanos et al.
CLINICAL IMMUNOLOGY (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Konstantinos Papamichael et al.
CURRENT OPINION IN GASTROENTEROLOGY (2019)
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease
Mark Lowenberg et al.
GASTROENTEROLOGY (2019)
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases
Siddharth Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Recent advances in monoclonal antibody therapy in IBD: practical issues
Aravind Gokul Tamilarasan et al.
FRONTLINE GASTROENTEROLOGY (2019)
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
W. Yacoub et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I
Simon R. Knowles et al.
INFLAMMATORY BOWEL DISEASES (2018)
Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot
Karien Bloem et al.
BIOANALYSIS (2018)
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
JOURNAL OF CROHNS & COLITIS (2018)
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review
Laura Martelli et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Sample Size for Assessing Agreement between Two Methods of Measurement by Bland-Altman Method
Meng-Jie Lu et al.
INTERNATIONAL JOURNAL OF BIOSTATISTICS (2016)
Sample Size for Assessing Agreement between Two Methods of Measurement by Bland-Altman Method
Meng-Jie Lu et al.
INTERNATIONAL JOURNAL OF BIOSTATISTICS (2016)
Use of anti-TNF drug levels to optimise patient management
Konstantinos Papamichael et al.
FRONTLINE GASTROENTEROLOGY (2016)
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2015)
Volumetric Absorptive Microsampling: A Dried Sample Collection Technique for Quantitative Bioanalysis
Philip Denniff et al.
ANALYTICAL CHEMISTRY (2014)
Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions
Abraham J. Wilhelm et al.
CLINICAL PHARMACOKINETICS (2014)
Targeting TNF-α for the treatment of inflammatory bowel disease
Thomas Billiet et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2014)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Review article: remission rates achievable by current therapies for inflammatory bowel disease
L. Peyrin-Biroulet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Rat C-reactive protein activates the autologous complement system
ND Padilla et al.
IMMUNOLOGY (2003)
Share Paper
